Company Filing History:
3 out of 5,089 
3 out of 1,744 
3 out of 23 
Years Active: 2022-2024
Title: Eduard Ayuso: Pioneering Innovations in Gene Therapy
Introduction
Eduard Ayuso, an innovative inventor based in Nantes, France, has made significant contributions to the field of gene therapy. With a portfolio boasting three patents, his pioneering work focuses on advancements in recombinant Adeno-Associated Virus (rAAV) vector particles, which play a critical role in gene delivery.
Latest Patents
Ayuso's most recent invention features a recombinant Adeno-Associated Virus (rAAV) vector particle that incorporates at least one primary amino group within the capsid proteins. This cutting-edge innovation involves the chemical coupling of ligands to the capsid through a specific bond comprising a —CSNH— connection and an optionally substituted aromatic moiety. His work emphasizes the ability to modulate ligand coupling on the surface of AAV capsids, such as AAV2 and AAV3b, enhancing gene delivery mechanisms. Furthermore, one notable application tested involved the chemical coupling of a mannose ligand on AAV2 for subretinal injection in rats. This invention also encompasses a method for creating such coupled Adeno-Associated Virus vector particles, along with a corresponding pharmaceutical composition and their medical uses.
Career Highlights
Throughout his career, Eduard Ayuso has been affiliated with prestigious research institutions, including the Centre National de la Recherche Scientifique (CNRS) and the Institut National de la Santé et de la Recherche Médicale (INSERM). His research in these esteemed organizations has played a vital role in developing innovative applications in the field of gene therapy.
Collaborations
Ayuso has collaborated with notable professionals in his field, including colleagues Mathieu Mevel and David Deniaud. These partnerships have undoubtedly advanced the quality and impact of his research endeavors, contributing to significant innovations in gene delivery systems.
Conclusion
Eduard Ayuso’s dedication to advancing gene therapy through the development of cutting-edge rAAV vector technology has positioned him as a significant figure in the realm of biomedical innovation. With a solid foundation of patents and collaborations, his contributions promise to facilitate groundbreaking advancements in therapeutic applications and enhance the effectiveness of gene delivery to target cells.